

# Author Correction: Aldo-keto reductase 1C2 (AKR1C2) as the second gene associated to non-syndromic primary lipedema: investigating activating mutation or overexpression as causative factors

J. KAFTALLI, K. DONATO, G. BONETTI, K. DHULI, A. MACCHIA, P.E. MALTESE, K. LOUISE HERBST, S. MICHELINI, P. CHIURAZZI, M. HILL, S. MICHELINI, S. MICHELINI, G. MARCEDDU, A. BERNINI, M. BERTELLI

MAGI EUREGIO, Bolzano, Italy


Correction to: Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 127-136–DOI: 10.26355/eurrev\_202312\_34697-published online on December 18, 2023.

After publication and following some post-publication concerns, the authors have applied the following corrections to the galley proof.

- The conflict of interest section has been amended as follows:

J. Kaftalli and G. Marceddu are employees at MAGI EUREGIO. K. Donato is employee at MAGI EUREGIO and MAGISNAT. M. Bertelli is president of MAGI EUREGIO, MAGISNAT, and MAGI's LAB. G. Bonetti, K. Dhuli, A. Macchia, and P.E. Maltese are employees at MAGI's LAB. M. Bertelli, P.E. Maltese, K. Louise Herbst, Sa. Michelini, Se. Michelini, and P. Chiurazzi are patent inventors (US20220362260A1). M. Bertelli, P.E. Maltese, G. Marceddu are patent inventors (US20230173003A1). M. Bertelli, K. Dhuli and P.E. Maltese are patent inventors (WO2022079498A1). M. Bertelli, P.E. Maltese, Sa. Michelini, Se. Michelini, P. Chiurazzi, K. Louise Herbst, J. Kaftalli, K. Donato, and A. Bernini are patent applicants (Application Number 18/516,241). M. Bertelli, K. Donato, P. Chiurazzi, G. Marceddu, K. Dhuli, G. Bonetti and J. Kaftalli are patent applicants (Application Number: 18/466.879). M. Bertelli, G. Bonetti, G. Marceddu, K. Donato, K. Dhuli, J. Kaftalli, Sa. Michelini, and K. Louise Herbst are patent applicants (Application Number 63/495,155). The remaining authors have no conflict of interest to disclose.

- Figure 5 has been modified as follows to better distinguish outliers:



- The legend of Figure 5 has to be modified as follows:

Relative expression of AKR1C1 and AKR1C3 in different groups (CTR = non affected controls, L = lipedema patients without overexpression of AKR1C2, L-over = Lipedema patients with overexpression of AKR1C2), showing that lipedema patients expressed AKR1C1 and AKR1C3 levels similar to the control group. Outliers are reported as black triangles.

There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.